Fujirebio Diagnostics, a cancer diagnostics company, has appointed Grady Barnes as its new chief scientific officer.
Subscribe to our email newsletter
As chief scientific officer, Dr Barnes will be responsible for all scientific affairs including R&D, product development, process engineering and clinical and regulatory affairs. Dr Barnes will also assist in the selection of new product candidates and licensing opportunities for Fujirebio Diagnostics products.
Dr Barnes has held various positions at Abbott and Meridian Bioscience, most recently as vice president of R&D at Meridian Bioscience.
Paul Touhey, president and CEO of Fujirebio Diagnostics, said: “Dr Barnes’s extensive experience in diagnostics will be vital to sustaining Fujirebio Diagnostics’s growth. His expertise will support the growth and acceptance of biomarker assays in ovarian cancer, such as HE4, and help Fujirebio Diagnostics identify additional promising biomarkers in oncology.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.